Introduction
============

Gastric cancer is the fifth leading cause of cancer deaths globally.[@B1] The prognosis of gastric cancer is poor because even after curative resection, advanced cancer has a high risk of recurrence despite adjuvant chemotherapy.[@B2][@B3][@B4][@B5]

To improve the response rate of chemotherapy, adenosine triphosphate-based chemotherapy response assays (ATP-CRAs) have been employed to individualize treatment.[@B6][@B7] It would be an ideal method for choosing the most effective patient-specific chemotherapy agent, provided that an in vitro assay could predict the in vivo chemo-responsiveness. The most attractive feature of this assay is that it can simultaneously test the sensitivity of multiple chemotherapy agents.

The distribution of tumor infiltrating lymphocytes (TILs) could also predict responses to neoadjuvant[@B8][@B9][@B10][@B11][@B12] and adjuvant chemotherapies[@B13][@B14][@B15] in solid cancers. TIL distribution is an independent prognostic marker for gastric cancer and other solid cancers.[@B8][@B10][@B16][@B17] Gastric medullary carcinomas that have extensive infiltration of lymphocytes often show excellent prognosis.[@B18]

Thus, improving predictions for chemo-responsiveness is a highly desirable possibility when combining ATP-CRA results and TIL distribution. The aim of the present study was to explore the possibility of selecting patient-specific sensitive chemotherapeutic agents based on TIL-related immune microenvironments.

Materials and Methods
=====================

1. Patients
===========

At Severance Hospital, Yonsei University College of Medicine, from February 2007 to January 2011, 15 patients were enrolled for the study with histologically proven gastric cancewr ho had undergone gastric resection surgery. All data on patients\' characteristics and pathological features of resected tumors were collected by a retrospective review of a prospectively maintained database. No patients were treated with neoadjuvant chemotherapies or had histories of another primary tumor. All patients agreed to the chemosensitivity test of their resected tumors and gave informed consent. This study was approved by the Yonsei Institutional Review Board (4-2011-0864).

2. Adenosine triphosphate-based-based chemotherapy response assays
==================================================================

ATP-CRAs were performed as previously described.[@B6] Briefly, a 0.5-cm^3^ sample of cancer tissue was collected, stored in Hank\'s balanced salt solution (GIBCO BRL, Rockville, MD, USA) containing 100 IU/ml penicillin (Sigma, St. Louis, MO, USA), 100 µg/ml streptomycin (Sigma), 100 µg/ml gentamicin (GIBCO BRL), 2.5 µg/ml amphotericin B (GIBCO BRL), and 5% fetal bovine serum (GIBCO BRL), and immediately sent to the pathology laboratory. Tissues were washed, quantified, minced, and enzymatically dissociated. Cells were purified by density centrifugation to eliminate debris. After dilution of the separated tumor cells to 2×10^4^ cells/ml, cells were seeded in triplicate in 96-well microplates (Costar, Cambridge, MA, USA).

In the treated groups, 100 µl of chemotherapeutic agents were added to the seeded cells, and 100 µl of Iscove\'s modified Dulbecco\'s medium (GIBCO BRL) without chemotherapeutic agent s were added to the untreated control groups. Samples from each patient were individually treated with each of the chemotherapeutic agents. The test drug concentrations were determined based one apk plasma concentrations according to previous reports: etoposid(e3 .57 µg/ml), doxorubicin (1.5 µg/ml), epirubicin (1.2 µg/ml), mitomycin (0.2 µg/ml), 5-fluorouracil (5-FU, 10 µg/ml), oxaliplatin (2.9 µg/ml), irinotecan (4.7 µg/ml), docetaxel (3.7 µg/ml), paclitaxel (8.5 µg/ml), methotrexate (0.37 µg/ml), and cisplatin (2.5 µg/ml).[@B19][@B20][@B21] Three different doses (0.2-, 1-, and 5-fold) of the test drug were used in triplicate. Microplates were cultured for 48 hours at 37℃ in 5% CO~2~. ATP levels in the cell lysates were measured using flash type luminescence measurements (Roche, Mannheim, Germany). Cancer cell death rates were determined as the ratio of ATP luminescence reduction in the treated groups compared to that of the untreated control.

3. Quantification of tumor infiltrating lymphocyte subsets
==========================================================

Immunohistochemical staining and quantification of TIL subsets was performed as previously described.[@B16] Paraffin-embedded gastric cancer tissue sections were serially sectioned at 4-µm, deparaffinized in xylene, and rehydrated in decreasing concentrations of ethanol. Antigen retrieval was performed in citrate buffer in a microwave. Endogenous peroxidase activity was blocked by incubating in 3% hydrogen peroxide in methan ol for 5 minutes. Sections were incubated for 60 minutes at room temperature (20℃ to 25℃) with primary monoclonal antibodies: CD3 (1:100; Lab Vision Corporation, Fremont, CA, USA), CD4 (1:100; Novocastra, Newcastle Upon Tyne, UK), CD8 (1:100; Novocastra), Foxp3, (forkhead/winged helix transcription factor 3, 1:100, ab20034; Abcam, Cambridge, UK), and Granzyme B (1:100; Lab Vision Corporation), which were used to identify the following T lymphocyte subsets: total T lymphocytes, helper T lymphocytes, cytotoxic T lymphocytes, regulatory T cells, and activated cytotoxic T lymphocytes, respectively. Incubation in horseradish peroxidase-conjugated secondary antibody was subsequently performed, followed by development with diaminobenzidine and counterstaining with hematoxylin. Five high-power fields (×400) from each slide were selected for manual counting using an Olympus CX31 microscope (Olympus America, Center Valley, PA, USA). The absolute number of lymphocytes per high-power field was determined for each antibody (CD3, CD4, CD8, Foxp3, and Granzyme B). The median count number was used to divide the patients into low- and high-density groups.

4. Statistical analysis
=======================

Pearson\'s correlation tests were performed for cancer cell death rates and TIL subsets. Absolute numbers of cells positive for each stain were dichotomized using cut-off values derived by the median. Survival curves were constructed using the Kaplan-Meier method, and the log-rank test was used to evaluate the significance. A statistical significance level was defined as a P-value of 0.05 or less. All statistical analyses were performed with SAS 9.2 software (SAS Institute, Cary, NC, USA).

Results
=======

1. Clinicopathological characteristics
--------------------------------------

The clinicopathological features of 15 patients are presented in [Table 1](#T1){ref-type="table"}. Of 15 patients, 14 were male and 1 was female. The mean age was 58.9 years. The distribution of the stages according to 7th American Joint Committee on Cancer classification included seven stage II (46.7%), six stage III (40.0%), and two stage IV (13.3%).

2. In vitro chemosensitivity test results
-----------------------------------------

The cytotoxic effect of the chemotherapeutic agents tested at previously published peak plasma concentrations[@B19][@B20][@B21] ranged from 0% to 72.7% cell death ([Table 2](#T2){ref-type="table"}). The highest cancer cell death rates were seen in cells treated with etoposide (44.8%), 5-FU (43.1%), and mitomycin (39.9%). The rank of each chemotherapeutic agent among 11 agents was determined according to that cell death rate in each patient. The most active chemotherapeutic agent was etoposide, with the highest chemosensitivity, 60.0% (9/15) for the tested specimens. Ten patients who underwent 5-FU chemotherapy were categorized into higher- and lower-cell death rate groups based on their median cell death rates. The overall survival of these two groups was analyzed. The 5-FU-sensitive patients showed better survival, though the difference was not statistically significant (P=0.216; [Fig. 1A](#F1){ref-type="fig"}). Among the 15 patients, only two patients were treated with adjuvant chemotherapeutic agents as determined by ATP-CRAs (one with etoposide and one with cisplatin) that had the highest chemosensitivity results. Among the remaining 13 patients, 8 patients were treated with 5-FU based chemotherapeutic agents and 1 patient was treated with a docetaxel based chemotherapeutic agent. The other 4 patients did not received adjuvant chemotherapy. [Fig. 1B](#F1){ref-type="fig"} shows the survival comparison of patients who were treated according to ATP-CRA results or who were treated with chemotherapeutic agents chosen by their physician (P=0.105).

3. Subsets of tumor infiltrating lymphocytes
--------------------------------------------

The median number of cells positive for CD3, CD4, CD8, Foxp3, and Granzyme B were 156.0, 64.7, 80.7, 15.3, and 10, respectively ([Table 3](#T3){ref-type="table"}). Using the median values, all cases were classified into low- and high-density groups for each variable and survival rates were compared. A higher number of total T lymphocytes (CD3) was a good prognostic factor (P=0.008; [Fig. 1C](#F1){ref-type="fig"}).

4. Association between cancer cell death rates and tumor infiltrating lymphocyte subsets
----------------------------------------------------------------------------------------

Pearson\'s correlation tests showed no statistically significant association between cancer cell death rates as determined by ATP-CRA for each chemotherapeutic agent and the TIL subsets from the correlating patient ([Table 4](#T4){ref-type="table"}). Three pairings of chemotherapeutic agents/count number of TIL subsets, docetaxel-CD4, 5-FU-Granzyme B, and methotrexate-Granzyme B had marginal associations with correlation coefficients of -0.453, 0.506, and 0.477, respectively, and P-values of 0.090, 0.054, and 0.072, respectively ([Fig. 2A\~C](#F2){ref-type="fig"}). The most commonly used chemotherapeutic agents in Korea, 5-FU and cisplatin, also showed no significant association with the CD3 subset, which showed prognostic implications in this study ([Fig. 2D, E](#F2){ref-type="fig"}).

Discussion
==========

Accumulating evidence suggests that the immune microenvironment alters chemo-responsiveness.[@B22][@B23] Previous studies on chemo-responsiveness used various chemotherapeutic agents for different types of cancer. Thus, translation of the results to gastric cancer treatment is challenging. For example, high posttreatment levels of CD3 or CD8 TIL subsets in the tumor micro-environment correlates with more robust responses to paclitaxel neoadjuvant chemotherapy in breast cancer.[@B24] Additionally, the density of CD8 TILs affects the chemo-responsiveness to 5-FU in stage III colon cancer.[@B25] Higher densities of CD3, CD8, and Granzyme B, but not of Foxp3 TILs at invasive margins are related to improved chemo-responsiveness to irinotecan- and platinum-based chemotherapies in metastatic colorectal cancer.[@B26] Furthermore, the level of regulatory T cells prior to chemotherapy is a predictive marker for early breast cancer.[@B27] However, the relationship of the immune microenvironment and chemoresponsiveness in gastric cancer has never been studied. To explore whether cancer cell response to chemotherapeutic agents has any relationship with immune microenvironments, we investigated the association of cancer cell death rates in ATP-CRAs and the distribution of TIL subsets within the tumor tissue microenvironment. However, no significant associations were identified.

It is unknown whether TILs cause or enhance susceptibility to chemotherapeutic agents or are simply chemosensitivity markers. The current study suggests that TILs are more representative of susceptibility to chemotherapy rather than a marker of chemosensitivity. Our ATP-CRA and TIL analyses were separately performed using cultured cancer cells and immunohistochemical staining of tumor tissues. Thus, it may not completely and accurately represent the in situ interactive effects of chemotherapy on the tumor/host immune system. A subset of TILs in tumor microenvironments can modulate the susceptibility of chemotherapy against cancer cells.[@B9][@B28][@B29] Conversely, chemotherapy can enhance the efficacy of host immune functions by reducing tumor burdens and enhancing tumor cell susceptibility.[@B30] It is also known that tumor-associated antigens are released when chemotherapeutic agents destroy tumor cells.[@B9]

Limitations of this study include the small number of the patients, emphasizing the need for further validation of these observations in additional data sets; only a small portion of the patients were treated according to ATP-CRA results; and the biological mechanism underlying these observations was not studied. Despite these limitations, we tried to assess the association of chemosensitivity test results and TIL subsets in gastric cancer. No significant association between the two suggests that current ATP-CRA has limitations for predicting cancer cell destruction, which could be affected by the immune system.

In conclusion, cancer cell death rates in response to specific chemotherapeutic agents had a poor association with the distribution of TIL subsets.
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![Survival analysis according to chemotherapeutic agent choice and tumor infiltrating lymphocytes (TILs). (A) Survival of patients who were treated by 5-fluorouracil (5-FU) (P=0.216). From 15 patients, 10 patients underwent 5-FU adjuvant chemotherapy. According to median cell death rates in adenosine triphosphate-based chemotherapy response assays (ATP-CRAs), patients were grouped as sensitive (n=5) and insensitive (n=5) to 5-FU. (B) Survival of patients who were treated with therapeutic agents as determined by ATP-CRAs (n=2) versus those chosen by a physician (n=8) (P=0.105). (C) Survival of high- (n=5) and low-CD3 (n=5) patients. Of the various TIL subsets examined, only high numbers of CD3 TILs (total T lymphocytes) showed favorable prognosis (P=0.008).](jgc-15-223-g001){#F1}

![Pearson\'s correlation scatter plots for cell death rates in response to various chemotherapeutic agents in adenosine triphosphate-based chemotherapy response assays and tumor infiltrating lymphocyte subsets for 15 patients. (A) CD4-docetaxel cell death rate (CDR). (B) Granzyme B-5-fluorouracil (5-FU) CDR. (C) Granzyme B-Methotrexate CDR. (D) CD3-5-FU CDR. (E) CD3-cisplatin CDR. For all graphs, each point represents results from a single patient.](jgc-15-223-g002){#F2}

###### Clinicopathological features of patients
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Values are presented as number (%) or mean only. ^\*^Classification according to the standard of American Joint Committee on Cancer, 7th edition.

###### Cancer cell death rates following treatment with chemotherapeutic agents in adenosine triphosphate-based chemotherapy response assays
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###### Tumor infiltrating lymphocyte subsets within tumor tissues
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^\*^Number of cells per high-power field. ^†^Forkhead/winged helix transcription factor 3.

###### Pearson\'s correlations between tumor infiltrating lymphocyte subsets and cell death rates in response to chemotherapeutic agents
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